Myocardial Infarction, Acute Coronary Syndrome, ACS, hyperglycaemia Myocardinfarct, Acuut Coronair Syndroom, hyperglycaemie
Conditions
Interventions
Treatment for this study only involves managing glucose levels and will not interfere with other treatment strategies, which will be applied according to international guidelines for myocardial infarc
Sponsors
Foreest Institute Alkmaar
Eligibility
Inclusion criteria
Inclusion criteria: Patients to be included must meet the following three criteria: 1. Men or women >18 years of age who are admitted with the clinical diagnosis of a myocardial infarction. The diagnosis should be based on the combination of typical ischemic chest complaints and objective evidence of myocardial ischemia or myocardial necrosis as demonstrated by the electrocardiogram (ECG) or elevated cardiac markers, as follows: - Typical ischemic chest pain, lasting 10 minutes or more, with the onset of symptoms within the preceding 24 hours, and either - ECG changes indicative of myocardial ischemia within 24 hours after the onset of chest pain (ECG showing new persistent or non-persistent ST-segment elevation >1.0 mm in two or more contiguous leads) or - Elevated biomarkers of myocardial necrosis within 24 hours after the onset of chest pain (i.e. CK-MB >1 times the upper limit of normal of the laboratory ( >16 U/L), or Troponin-I > 0.45 ng/ml). 2. Elevated (>7.8 mmol/L) whole blood glucose at admission in patients without a history of insulin dependent diabetes mellitus. (Patients only on oral anti-diabetic agents (NIDDM) can be included) 3. All patients have to provide written informed consent.
Exclusion criteria
Exclusion criteria: Patients will be excluded from this study for any of the following reasons: 1. Myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease (e.g. arrhythmia, severe anemia, hypoxia, thyrotoxicosis, cocaine, severe valvular disease, hypotension). 2. Known severely-impaired left ventricular function (ejection fraction <30%) or end-stage congestive heart failure NYHA-class III or IV at presentation (in order to avoid lost-to-follow-up due to non-acute coronary syndrome events). 3. Severe chronic kidney disease with measured or calculated glomerular filtration rate (Cockgroft-Gault or MDRD4 (Modification of Diet in Renal Disease) formula) of <30 ml/min/1.73m2, or renal dialysis38. 4. Persistent atrial fibrillation. 5. Co-existent condition associated with a life-expectancy <1 year, or otherwise unlikely to appear at all scheduled follow-up visits. 6. Patient expected to be transferred to another hospital within 48 hours. 7. Insulin Dependent Diabetes Mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Extent of myocardial damage expressed by Troponin T level at 72 hours (48 - 96 hours) after admission. If more than one sample is drawn in this time frame, the sample closest to 72 hours will be used. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Differences in biomarker wash out patterns between intensive and regularly treated patients; 2. Left Ventricle Ejection Fraction (LVEF) and infarct size will be measured using a 99mTc-sestamibi SPECT 6 weeks after the event (+/- 1 week).This as we expect the remodelling of the heart has settled at this stage; 3. Extend of myocardial damage as expressed by area under CKMB curve. The CKMB curve will be made of serial measurements of CKMB; at presentation and 6, 12, 24, 36, and 72 hours after enrolment; 4. ST segment resolution; 5. Serum NTpro BNP values; 6. Mortality and non fatal re-infarction (>72 hr after primary event) at 6 weeks; 7. HbA1C and fasting glucose values at 6 weeks; 8. The area under the Troponin T wash out curve (AUC) using the samples collected during admission. | — |
Contacts
Public ContactV.A.W.M. Umans
Cardiology dept. Medical Center Alkmaar PO box 1800
Outcome results
None listed